Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Pharmaco-Immunomodulatory Therapy in COVID-19

The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory response. The cytokine storm and viral evasion of cellular immune responses may play an equally important role in the pathogenesis, clinical manifestation, and outcomes of COVID-19. Systemic proinflammatory cytokines and biomarkers are elevated as the disease progresses towards its advanced stages, and correlate with worse chances of survival. Immune modulators have the potential to inhibit cytokines and treat the cytokine storm. A literature search using PubMed, Google Scholar, and ClinicalTrials.gov was conducted through 8 July 2020 using the search terms 'coronavirus', 'immunology', 'cytokine storm', 'immunomodulators', 'pharmacology', 'severe acute respiratory syndrome 2', 'SARS-CoV-2', and 'COVID-19'. Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g. baricitinib, ruxolitinib), anti-tumor necrosis factor-α (e.g. adalimumab, infliximab), granulocyte-macrophage colony-stimulating factors (e.g. gimsilumab, lenzilumab, namilumab), and convalescent plasma, with promising to negative trials and other data. Non-specific immune modulators include human immunoglobulin, corticosteroids such as dexamethasone, interferons, statins, angiotensin pathway modulators, macrolides (e.g. azithromycin, clarithromycin), hydroxychloroquine and chloroquine, colchicine, and prostaglandin D2 modulators such as ramatroban. Dexamethasone 6 mg once daily (either by mouth or by intravenous injection) for 10 days may result in a reduction in mortality in COVID-19 patients by one-third for patients on ventilators, and by one-fifth for those receiving oxygen. Research efforts should focus not only on the most relevant immunomodulatory strategies but also on the optimal timing... Full description

Year of Publication: 2020
Contained in: Drugs Vol. 80, No. 13 (2020), p. 1267-1292
All journal articles: Search for all articles in this journal
Language: English
Contributors: Rizk, John G | Author
Kalantar-Zadeh, Kamyar
Mehra, Mandeep R
Lavie, Carl J
Rizk, Youssef
Forthal, Donald N
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: Immunologic Factors
Journal Article
Review
Additional Keywords: *Coronavirus Infections
*Immunologic Factors
*Pandemics
*Pneumonia, Viral
Betacoronavirus
Humans
Immunomodulation
Treatment Outcome
ISSN: 1179-1950
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 16.09.2020
Date Revised 22.09.2020
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32696108
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1007/s40265-020-01367-z
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04201nma a2200565 c 4500
001 NLM313644055
003 DE-601
005 20200922213753.0
007 cr uuu---uuuuu
008 200722s2020 000 0 eng d
024 7 |a 10.1007/s40265-020-01367-z  |2 doi 
028 5 2 |a pubmed20n1347.xml 
035 |a (DE-599)NLM32696108 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Rizk, John G 
245 1 0 |a Pharmaco-Immunomodulatory Therapy in COVID-19  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 16.09.2020 
500 |a Date Revised 22.09.2020 
500 |a published: Print 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory response. The cytokine storm and viral evasion of cellular immune responses may play an equally important role in the pathogenesis, clinical manifestation, and outcomes of COVID-19. Systemic proinflammatory cytokines and biomarkers are elevated as the disease progresses towards its advanced stages, and correlate with worse chances of survival. Immune modulators have the potential to inhibit cytokines and treat the cytokine storm. A literature search using PubMed, Google Scholar, and ClinicalTrials.gov was conducted through 8 July 2020 using the search terms 'coronavirus', 'immunology', 'cytokine storm', 'immunomodulators', 'pharmacology', 'severe acute respiratory syndrome 2', 'SARS-CoV-2', and 'COVID-19'. Specific immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g. baricitinib, ruxolitinib), anti-tumor necrosis factor-α (e.g. adalimumab, infliximab), granulocyte-macrophage colony-stimulating factors (e.g. gimsilumab, lenzilumab, namilumab), and convalescent plasma, with promising to negative trials and other data. Non-specific immune modulators include human immunoglobulin, corticosteroids such as dexamethasone, interferons, statins, angiotensin pathway modulators, macrolides (e.g. azithromycin, clarithromycin), hydroxychloroquine and chloroquine, colchicine, and prostaglandin D2 modulators such as ramatroban. Dexamethasone 6 mg once daily (either by mouth or by intravenous injection) for 10 days may result in a reduction in mortality in COVID-19 patients by one-third for patients on ventilators, and by one-fifth for those receiving oxygen. Research efforts should focus not only on the most relevant immunomodulatory strategies but also on the optimal timing of such interventions to maximize therapeutic outcomes. In this review, we discuss the potential role and safety of these agents in the management of severe COVID-19, and their impact on survival and clinical symptoms 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Betacoronavirus  |6 D000073640  |a physiology  |6 Q000502 
653 2 |a *Coronavirus Infections  |6 D018352  |a drug therapy  |6 Q000188  |a immunology  |6 Q000276 
653 2 |a Humans  |6 D006801 
653 2 |a *Immunologic Factors  |6 D007155  |a classification  |6 Q000145  |a pharmacology  |6 Q000494 
653 2 |a Immunomodulation  |6 D056747  |a *immunology  |6 Q000276 
653 2 |a *Pandemics  |6 D058873 
653 2 |a *Pneumonia, Viral  |6 D011024  |a drug therapy  |6 Q000188  |a immunology  |6 Q000276 
653 2 |a Treatment Outcome  |6 D016896 
655 7 |a Immunologic Factors  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Review 
689 0 |5 DE-601 
689 2 0 |a Immunologic Factors 
689 2 |5 DE-601 
700 1 |a Kalantar-Zadeh, Kamyar 
700 1 |a Mehra, Mandeep R 
700 1 |a Lavie, Carl J 
700 1 |a Rizk, Youssef 
700 1 |a Forthal, Donald N 
773 0 8 |i in  |t Drugs  |g Vol. 80, No. 13 (2020), p. 1267-1292  |q 80:13<1267-1292  |w (DE-601)NLM000016136  |x 1179-1950 
856 4 1 |u http://dx.doi.org/10.1007/s40265-020-01367-z  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 80  |j 2020  |e 13  |b 21  |c 09  |h 1267-1292